Windward Bio Group AG
WWB
New listing · first traded Nov 13, 2026 on Nasdaq · source: SEC EDGAR
Below: live stock price for Windward Bio Group AG (WWB), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.
Windward Bio Group AG (WWB) is a Healthcare company based in Switzerland. Operating in Biotechnology, it employs about 33 people. Over the past year WWB traded between 18.35 and 33.99 USD.
- Prev close
- $24.01
- Volume (24h)
- $3.85M
- Market cap
- $1.41B
- Currency
- USD
Scoreas of Nov 21, 2026
54/ 100 · Mixed
- Value88
- Quality13
- Momentum23
- Growth—
- Risk100
- Dividend0
- Liquidity100
Composite of public market data. Informational only — not investment advice.
Trend projection
Not enough history to project a trend.
Interpretation
The composite score is in the mixed range. Strength: risk profile with weakness: dividend.
Descriptive observation — not investment advice.
Score breakdown
Raw values behind each pillar so you can see what the composite is reading.
- Value88/100
Value looks strong — driven by P/B (1.42).
P/B:1.42 - Quality13/100
Quality looks fragile — driven by Profit margin (0.00%).
Profit margin:0.00%Gross margin:0.00% - Momentum23/100
Momentum looks fragile — driven by 52w change (-14.77%).
52w change:-14.77% - Risk100/100
Risk looks strong — driven by Debt / equity (0.18).
Debt / equity:0.18 - Dividend0/100
Dividend looks fragile — driven by Dividend yield (0.00%).
Dividend yield:0.00% - Liquidity100/100
Liquidity looks strong — driven by Current ratio (8.57).
Current ratio:8.57Quick ratio:8.49
Derived from public market data — informational, not investment advice.
Pivot points
Daily, from the November 20 session's high, low and close
High 26.20 · Low 22.47 · Close 24.29
| Level | Classic | Fibonacci | Camarilla |
|---|---|---|---|
| R3 | 29.90 | 28.05 | 25.31 |
| R2 | 28.05 | 26.62 | 24.97 |
| R1 | 26.17 | 25.74 | 24.63 |
| Pivot | 24.32 | 24.32 | 24.32 |
| S1 | 22.44 | 22.89 | 23.94 |
| S2 | 20.59 | 22.01 | 23.60 |
| S3 | 18.71 | 20.59 | 23.26 |
Pivot points are reference levels computed with standard formulas from the previous session's range. They are not a forecast and not a buy or sell signal.
Weekly and monthly pivots, Woodie and DeMark: pivot point calculator →Historical data
Daily prices for the latest sessions, newest first
| Date | Close | Open | High | Low | Volume | Change % |
|---|---|---|---|---|---|---|
| Nov 20, 2026 | 24.29 | 24.49 | 26.20 | 22.47 | 3.85M | +1.15% |
| Nov 19, 2026 | 24.01 | 22.01 | 25.00 | 21.12 | 3.99M | +6.05% |
| Nov 18, 2026 | 22.64 | 25.51 | 29.95 | 21.01 | 11.73M | -12.11% |
| Nov 17, 2026 | 25.76 | 29.67 | 29.67 | 21.38 | 6.34M | -14.25% |
| Nov 16, 2026 | 30.04 | 25.00 | 32.00 | 22.50 | 7.14M | +5.40% |
Financials
- 52w high
- $33.99
- 52w low
- $18.35
- 52w change
- -14.77%
- Day high
- $26.20
- Day low
- $22.47
- Price / Book
- 1.42
- Enterprise value
- 1.22B
- EV / EBITDA
- -16.74
- EPS (TTM)
- -$1.18
- Dividend yield
- 0.00%
- EBITDA
- -73.09M
- Total cash
- 186.47M
- Total debt
- 474K
- Debt / Equity
- 0.18
- Current ratio
- 8.57
- Quick ratio
- 8.49
- Profit margin
- 0.00%
- Gross margin
- 0.00%
- Shares outstanding
- 58.04M
- Float
- 14.69M
Windward Bio Group AG operates as a clinical stage biotechnology company that develops ultra-long-acting antibody medicines for patients with respiratory and dermatologic diseases. Its drug candidates WIN378, an ultra-long-acting and novel fully human monoclonal antibody, which has completed Phase I clinical study that inhibits thymic stromal lymphopoietin (TSLP); and WIN027, an ultra-long-acting bispecific antibody that is in Phase I clinical study simultaneously targets TSLP and interleukin-13 (IL-13) and two clinically validated drivers of inflammatory disease. The company has collaboration agreements with Sichuan Kelun-Biotech BioPharmaceutical Co., Ltd, Harbour BioMed (Shanghai) Co., Ltd, and Qyuns Therapeutics Co., Ltd. Windward Bio Group AG was incorporated in 2024 and is based in Basel, Switzerland.
Analyst & Risk
Analysts' consensus via Yahoo Finance — not investment advice.
- 52-week change
- -14.77%
- Debt / Equity
- 0.18
- low leverage
- Current ratio
- 8.57
- Quick ratio
- 8.49
- EV / EBITDA
- -16.74
- EBITDA
- -73.09M
- Total cash
- 186.47M
- Total debt
- 474K
- Insider holdings
- 13.71%
- Institutional
- 43.62%
Analyst estimates
Consensus of research analysts' forecasts, compiled by Yahoo Finance · as of Nov 21, 2026
| Period | EPS estimate | EPS vs a year earlier | Revenue estimate | Revenue vs a year earlier |
|---|---|---|---|---|
| Current quarter | — | — | 0range 0 – 00 analysts | — |
| Next quarter | — | — | 0range 0 – 00 analysts | — |
| Current fiscal year | — | — | 0range 0 – 00 analysts | — |
| Next fiscal year | — | — | 0range 0 – 00 analysts | — |
Financial documents
Recent news
- Windward Bio to Participate at the Jefferies London Global Healthcare ConferenceGlobeNewswire3 days ago
- Windward Bio Announces Closing of $251.2 Million Initial Public Offering and Concurrent Private Placement, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewswire4 days ago
- Can Windward Bio Group (WWB) Trade At A Premium After Its IPO?Simply Wall St.6 days ago
- Windward Bio Group (WWB) Shares Jumped, What Is Behind The Move?Simply Wall St.6 days ago
- Innovative Immunology Biotech Windward Bio Lists on NasdaqPR Newswire7 days ago
- Innovative Immunology Biotech Windward Bio Lists on NasdaqPR Newswire7 days ago
- Windward Bio Announces Pricing of Initial Public OfferingGlobeNewswire8 days ago
- Novo Nordisk-Backed Windward Bio Group Files for US IPO, Plans Nasdaq Listing Under 'WWB'MT Newswires28 days ago
Related
Other assets in this category.
Live discussion
Sign in to join the discussion.